XFOR
Income statement / Annual
Last year (2023), X4 Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, X4 Pharmaceuticals, Inc.'s net income was -$101.17 M.
See X4 Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$3.00 M
|
$0.00
|
$3.50 M
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$2.00 M |
$1.99 M |
$1.89 M |
$0.00 |
$672,000.00 |
$103,000.00 |
$195,000.00 |
$300,000.00 |
$400,000.00 |
| Gross Profit |
-$2.00 M |
-$1.99 M |
-$1.89 M |
$3.00 M |
-$672,000.00 |
$3.40 M |
-$195,000.00 |
-$300,000.00 |
-$400,000.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
1 |
0 |
0.97 |
0 |
0 |
0 |
| Research and Development
Expenses |
$72.02 M
|
$61.06 M
|
$50.65 M
|
$41.93 M
|
$30.16 M
|
$30.98 M
|
$28.13 M
|
$17.83 M
|
$12.71 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$24.70 M
|
$20.94 M
|
$17.64 M
|
$18.41 M
|
$8.01 M
|
$6.52 M
|
$2.12 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$35.51 M
|
$27.02 M
|
$24.70 M
|
$20.94 M
|
$17.64 M
|
$18.41 M
|
$8.01 M
|
$6.52 M
|
$2.12 M
|
| Other Expenses |
$0.00 |
-$6.27 M |
-$3.57 M |
-$2.11 M |
-$1.10 M |
-$85,000.00 |
-$16,000.00 |
$104,000.00 |
-$77,000.00 |
| Operating Expenses |
$107.52 M |
$88.08 M |
$75.35 M |
$62.87 M |
$47.80 M |
$46.21 M |
$32.27 M |
$21.96 M |
$12.67 M |
| Cost And Expenses |
$107.52 M |
$88.08 M |
$75.35 M |
$62.87 M |
$47.80 M |
$46.21 M |
$32.27 M |
$21.96 M |
$12.67 M |
| Interest Income |
$4.58 M |
$219,000.00 |
$10,000.00 |
$273,000.00 |
$1.20 M |
$809,000.00 |
$214,000.00 |
$0.00 |
$0.00 |
| Interest Expense |
$5.78 M |
$3.99 M |
$3.64 M |
$2.69 M |
$2.15 M |
$1.04 M |
$2.08 M |
$2.52 M |
$472,000.00 |
| Depreciation &
Amortization |
$419,000.00
|
$1.99 M
|
$1.89 M
|
$1.23 M
|
$672,000.00
|
$103,000.00
|
$195,000.00
|
$300,000.00
|
$389,000.00
|
| EBITDA |
-$107.10 M
|
-$87.57 M
|
-$85.11 M
|
-$58.07 M
|
-$51.70 M
|
-$45.89 M
|
-$31.60 M
|
-$20.16 M
|
-$12.35 M
|
| EBITDA Ratio |
0 |
0 |
0 |
-19.96 |
0 |
-11.95 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
-19.96
|
0
|
-13.11
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$6.43 M
|
-$6.27 M
|
-$3.57 M
|
-$2.11 M
|
-$1.10 M
|
$2.86 M
|
$2.26 M
|
$6.48 M
|
$1.61 M
|
| Income Before Tax |
-$101.09 M |
-$93.84 M |
-$88.68 M |
-$61.98 M |
-$52.81 M |
-$43.02 M |
-$33.88 M |
-$22.98 M |
-$13.22 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
-20.66
|
0
|
-12.29
|
0
|
0
|
0
|
| Income Tax Expense |
$78,000.00 |
$28,000.00 |
$17,000.00 |
$148,000.00 |
$3.80 M |
$3.90 M |
$1.87 M |
$2.62 M |
$395,000.00 |
| Net Income |
-$101.17 M |
-$93.87 M |
-$88.70 M |
-$62.13 M |
-$56.60 M |
-$43.02 M |
-$33.88 M |
-$22.98 M |
-$13.22 M |
| Net Income Ratio |
0 |
0 |
0 |
-20.71 |
0 |
-12.29 |
0 |
0 |
0 |
| EPS |
-0.57 |
-1.48 |
-3.44 |
-3.09 |
-4.91 |
-93.73 |
-98.58 |
-24.76 |
-14.24 |
| EPS Diluted |
-0.57 |
-1.48 |
-3.44 |
-3.09 |
-4.91 |
-93.73 |
-98.58 |
-24.76 |
-14.24 |
| Weighted Average Shares
Out |
$177.81 M
|
$63.53 M
|
$25.75 M
|
$20.08 M
|
$11.53 M
|
$459,000.00
|
$343,641.00
|
$928,006.00
|
$928,006.00
|
| Weighted Average Shares
Out Diluted |
$177.81 M
|
$63.53 M
|
$25.75 M
|
$20.08 M
|
$11.53 M
|
$459,000.00
|
$343,641.00
|
$928,006.00
|
$928,006.00
|
| Link |
|
|
|
|
|
|
|
|
|
